secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2022-12-15T23:59:59+00:00
Accession:  0000939767-22-000121
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis announces CSO transition; Peter Lamb steps down; Dana Aftab promoted
-----------------------------------------------------------------------------

- Peter Lamb transitions from CSO to EVP, Scientific Strategy effective December 15, 2022.
- Dana T. Aftab, Ph.D., appointed as new CSO and EVP, Discovery and Translational Research.
- Dr. Aftab has over 24 years at Exelixis, most recently EVP, Business Operations.
- He previously led discovery and development of cabozantinib and streamlined translational processes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976722000121/0000939767-22-000121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976722000121/exel-20221215.htm
  HTML page:      https://secwatch.observer/filing/0000939767-22-000121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer